MD Anderson collaborating with Ascentage, Nanobiotix on clinical testing of cancer assets

The University of Texas MD Anderson Cancer Center unveiled two new partnerships with China's Ascentage Pharma Group International (Suzhou, China) and France's Nanobiotix S.A. (Euronext:NANO) for clinical testing of their respective cancer assets.

MD Anderson's collaboration with Nanobiotix will initially focus on nine Phase I/II clinical trials of NBTXR3 (PEP503) across different radiation modalities for head and neck, pancreatic, thoracic, lung, gastrointestinal and genitourinary cancers. The trials, most of which are slated to begin this year, will evaluate NBTXR3 as monotherapy or in combinations with checkpoint inhibitors. NBTXR3 comprises crystalline nanoparticles of hafnium oxide activated in vivo via standard radiation therapy...